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ABSTRACT 
 
Follicular lymphoma is the most common indolent lymphoma. It is composed of centro-
cytes and centroblasts, residing in follicles that also harbour nonmalignant immune and 
stroma cells. Follicular lymphoma is graded according to the World Health Organization 
criteria that are based on the frequency of centroblasts. There is consensus that grades 1 and 
2 are indolent, but not whether grade 3 is aggressive. Differences between grades 3A and 
3B are also unclear. The nonmalignant cells in the microenvironment interact with the 
tumour cells and with each other. These interactions may be important for disease outcome. 
Since the introduction of the therapeutic monoclonal anti-CD20 antibody rituximab, the 
prognosis of follicular lymphoma has improved. It is likely that the mechanisms of rituxi-
mab affect and involve not only CD20+ follicular lymphoma cells but also the surrounding 
as well as the systemic immune cells. The aim of this thesis was to identify biological 
predictors for outcome in follicular lymphoma in relation to therapy. 
 
In paper I, using flow cytometry, we reported that higher numbers of CD8+ T cells in dia-
gnostic lymph nodes are an independent predictor of better overall and disease-specific 
survival. This finding was reproduced in paper II in which computerised quantifications of 
tissue microarrays were used for a unifying multivariate model. This model showed that 
many cells in the microenvironment were independently important for outcome. Higher 
levels of cells positive for CD8 (cytotoxic T cells), forkhead box protein 3 (regulatory T 
cells) and programmed death-1 (PD-1+ T cells) correlated with good prognosis, but higher 
levels of cells positive for CD4 (helper T cells) and CD68 (macrophages) with poor. The 
best predictors for poor outcome were increasing CD4/CD8 and follicular/interfollicular 
CD4 ratios, suggesting that outcome is influenced by the balance between detrimental 
follicular B-helper and helper2 T-cells on one hand and favourable cytotoxic and helper1 T 
cells on the other. In paper III we used prospectively recorded flow cytometry analyses 
from two randomised trials where all patients received single rituximab with or without 
interferon-α priming. T cells in tumours (both CD4+ and CD8+) were associated with fast 
and good clinical responses to rituximab, while T cells in blood (both CD4+ and CD8+) 
correlated with slower but good and sustained responses, and were more important for 
survival. Interferon-α abrogated the dependence on high numbers of CD8+ cells (in both 
blood and tumours) for good rituximab responses. In paper IV we reviewed the follicular 
lymphoma grades in 828 patients with long follow-up times, of whom 40% received 
upfront rituximab. Compared with grade 1–3A patients and independently of clinical 
factors, grade 3B patients showed higher mortality but outcome was improved after upfront 
anthracyclines. Grade 3B patients experienced no relapses or deaths beyond five years of 
follow-up. Furthermore, patients with grade 3B were different in their clinical charac-
teristics. In the entire population, patients with grade 3A had similar outcome as those with 
grade 1–2. However, in patients given upfront rituximab-containing therapy, increasing 
grades of 1, 2, and 3A correlated with better overall survival and time to treatment-failure, 
independently of clinical factors. 
 
We conclude that outcome in follicular lymphoma is determined by the balance between 
competing immune cells in the microenvironment and by their interactions with each other 
and with the tumour cells. Rituximab and interferon-α alter the prognostic properties of the 
immune cells, and also involve systemic T cells that may be very important for disease 
outcome. Grade 3B, or follicular large B-cell lymphoma, is a distinct, aggressive but 
curable entity. Grades 1, 2 and 3A are indolent and incurable. Increasing grades predict 
better outcome with rituximab therapy. Our findings suggest a future of personalised 
therapy based on biological characteristics of the patients and of the tumours. 
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